Takeda have trialled a new health economic model review service, and are finding it to be a valuable resource for assessing and demonstrating the efficacy and value of their products. PRIMA, which stands for Preliminary Independent Model Advice, is a comprehensive, peer review service to help developers of drugs, medical devices and diagnostics, and public health interventions ensure the quality of their model structure, coding, usability and transparency. NICE Scientific Advice (NSA) launched the new health economic model review service in December 2017. Takeda completed two PRIMA projects with the organisation, and are pleased to now endorse the system.
Peter Wheatley-Price, Market Access and Pricing Director at Takeda UK Ltd, said: “Demonstrating patient value is one of our strategic priorities at Takeda. The creation of robust technology appraisals is therefore an important part of our daily work. We were delighted to be one of the first companies to work with the PRIMA service, and collaborate with NICE on improving this valuable tool".